March 9, 2005 Given the negative tone of the stock market in general, biotech did relatively well on Wednesday: the Centient Biotech 200 was down only 14 points at 3182.53, a relatively benign drop of .44%. The NYSE Composite lost .96%, and Nasdaq gave up .59%. We discuss another acquisition for Johnson and Johnson, some good news for troubled Immune Response, lowered earnings expectations for Lilly, turmoil in the CEO chair at NeoPharm, rivalry between Plavix and a new competitor, speculation that NPS Pharma may not find a marketing partner for Preos, its osteoporosis drug, and success (so far) for a Sleeping Sickness vaccine from Immtech. We flesh out these stories...
